Cancer Monoclonal Antibody Testing Market Size, Trends and Insights By Type of Cancer (Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Others), By Monoclonal Antibody Type (Rituximab, Trastuzumab, Bevacizumab, Cetuximab, Others), By Testing Method (Immunohistochemistry (IHC), Flow Cytometry, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Others), By End-User (Hospitals, Diagnostic Laboratories, Research Institutions, Others), and By Region - Global Industry Overview, Statistical Data, Competitive Analysis, Share, Outlook, and Forecast 2024–2033
Report Snapshot
| Study Period: | 2024-2033 |
| Fastest Growing Market: | Asia-Pacific |
| Largest Market: | Europe |
Major Players
- Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Bristol Myers Squibb Company
- Johnson & Johnson
- Novartis International AG
- Others
Reports Description
As per the current market research conducted by CMI Team, the global Cancer Monoclonal Antibody Testing Market is expected to record a CAGR of 7.6% from 2024 to 2033. In 2024, the market size is projected to reach a valuation of USD 90.5 Billion. By 2033, the valuation is anticipated to reach USD 175.1 Billion.
The Cancer Monoclonal Antibody Testing Market involves the development, production, and commercialization of diagnostic tests that utilize monoclonal antibodies to identify specific cancer markers. These tests play a pivotal role in cancer diagnosis, aiding in the detection of biomolecules associated with various cancer types.
Key players in the market focus on advancing technologies, such as targeted therapies and personalized medicine, to enhance diagnostic precision. The market is characterized by ongoing research and development efforts, collaborations, and innovations aimed at improving the accuracy and efficiency of monoclonal antibody testing, contributing to the global fight against cancer.
Cancer Monoclonal Antibody Testing Market – Significant Growth Factors
The Cancer Monoclonal Antibody Testing Market presents significant growth opportunities due to several factors:
- Rising Incidence of Cancer: The increasing prevalence of cancer globally is a significant driver, creating a growing demand for accurate and effective diagnostic tools, including monoclonal antibody testing.
- Advancements in Biotechnology: Ongoing advancements in biotechnology contribute to the development of novel monoclonal antibodies, enhancing the specificity and sensitivity of cancer diagnostics.
- Shift towards Personalized Medicine: The trend towards personalized medicine drives the demand for precise and targeted diagnostic approaches, with monoclonal antibody testing playing a crucial role in identifying specific biomarkers.
- Government Initiatives and Funding: Supportive government initiatives and increased funding for cancer research propel the development of innovative monoclonal antibody testing methods, fostering market growth.
- Technological Integration and Automation: The opportunity lies in the integration of advanced technologies, such as artificial intelligence and automation, to streamline and enhance the efficiency of monoclonal antibody testing processes.
- Expansion in Emerging Markets: There is a significant opportunity for market expansion in emerging economies where healthcare infrastructure is improving. Collaborations, strategic partnerships, and targeted marketing can facilitate increased adoption of monoclonal antibody testing in these regions.
Cancer Monoclonal Antibody Testing Market – Mergers and Acquisitions
The Cancer Monoclonal Antibody Testing Market has seen several mergers and acquisitions in recent years, with companies seeking to expand their market presence and leverage synergies to improve their product offerings and profitability. Some notable examples of mergers and acquisitions in the Cancer Monoclonal Antibody Testing Market include:
- In 2023, AstraZeneca India partnered with Roche Diagnostics India to enhance diagnostic testing for breast cancer patients, particularly focusing on streamlining HER2 diagnostics. This collaboration aims to leverage new advancements in the field, improving precision and efficiency in breast cancer diagnostics.
- In 2022, G42 Healthcare and AstraZeneca have entered a strategic partnership to manufacture pharmaceutical products in Abu Dhabi. This collaboration aims to enhance local manufacturing capabilities and contribute to the production of essential pharmaceuticals, advancing healthcare accessibility in the region.
- In 2022, Helio Genomics, in partnership with Fulgent Genetics, secured a new Category I CPT code from the AMA for HelioLiver, enhancing the adoption of advanced surveillance tests for liver cancer in the U.S. This achievement expands the company’s product portfolio and market reach.
These mergers and acquisitions have helped companies expand their product offerings, improve their market presence, and capitalize on growth opportunities in the Cancer Monoclonal Antibody Testing Market. The trend is expected to continue as companies seek to gain a competitive edge in the market.
COMPARATIVE ANALYSIS OF THE RELATED MARKET
| Cancer Monoclonal Antibody Testing Market | Polyclonal Antibody Market | Animal Biotechnology Market |
| CAGR 7.6% (Approx) | CAGR 4.5% (Approx) | CAGR 8.5% (Approx) |
| USD 175.1 Billion by 2033 | USD 6.5 Billion by 2032 | USD 68.2 Billion by 2032 |
Cancer Monoclonal Antibody Testing Market – Significant Threats
The Cancer Monoclonal Antibody Testing Market faces several significant threats that could impact its growth and profitability in the future. Some of these threats include:
- Regulatory Challenges: Stringent regulatory requirements and the need for extensive clinical validation pose a significant threat to the Cancer Monoclonal Antibody Testing Market. Delays or failures in obtaining regulatory approvals can hinder product launches and market entry.
- High Development Costs: The substantial costs associated with the research, development, and clinical trials of monoclonal antibody tests for cancer create financial barriers. Companies may face challenges in funding these high-cost initiatives, impacting market competitiveness.
- Competition and Market Saturation: Intense competition among pharmaceutical and biotechnology companies can lead to market saturation. Overcrowding with similar products may result in pricing pressures and reduced profit margins for monoclonal antibody testing.
- Emergence of Alternative Diagnostic Technologies: Advances in alternative diagnostic technologies, such as liquid biopsy and next-generation sequencing, pose a threat to traditional monoclonal antibody testing. Competing technologies that offer non-invasive or more comprehensive diagnostic information may shift market preferences.
- Global Economic Uncertainty: Economic downturns and uncertainties on a global scale can impact healthcare budgets, affecting investment in diagnostic technologies. Reduced funding and resource allocation to healthcare systems may limit the adoption of monoclonal antibody testing, posing a threat to market growth.
Category-Wise Insights:
By Type of Cancer
- Breast Cancer: Monoclonal antibody testing in breast cancer involves identifying specific biomarkers, such as HER2/neu or hormone receptors. Trends in this segment include the development of targeted therapies like Herceptin, personalized medicine approaches based on molecular subtypes, and the integration of advanced technologies for more precise and tailored diagnostics.
- Lung Cancer: Monoclonal antibody testing for lung cancer targets specific markers, such as EGFR or PD-L1. Market trends in this segment encompass the rapid growth of precision medicine, advancements in immunotherapy utilizing monoclonal antibodies, and a concerted effort towards early detection strategies through novel biomarker identification.
- Colorectal Cancer: Monoclonal antibody testing for colorectal cancer focuses on identifying biomarkers like CEA. Market trends in this segment involve an increased emphasis on population-wide screening programs, ongoing research into novel biomarkers for improved diagnostic accuracy, and the continuous development of personalized treatment options based on molecular profiling.
- Prostate Cancer: Monoclonal antibody testing in prostate cancer aims at detecting specific antigens like PSA. Market trends for this segment include research into novel biomarkers for early detection, the exploration of personalized treatment approaches based on molecular characteristics, and the integration of innovative technologies, such as liquid biopsy methods.
- Others: Monoclonal antibody testing for other cancers targets diverse biomarkers associated with specific types. Market trends in this category encompass a wide range of research efforts, the continuous development of targeted therapies for various cancers, and the exploration of new diagnostic applications, extending the reach of monoclonal antibody testing across different cancer types.
By Monoclonal Antibody Type
- Rituximab: Rituximab is a monoclonal antibody used to treat certain types of cancer, primarily non-Hodgkin lymphoma. Increasing adoption for lymphoma diagnostics, ongoing research for expanded applications, and collaborations for improved efficacy characterize the Rituximab segment in the Cancer Monoclonal Antibody Testing Market.
- Trastuzumab: Trastuzumab is a monoclonal antibody targeting HER2-positive breast cancer cells. Growing emphasis on HER2 testing, personalized treatment approaches, and continuous advancements contribute to the expansion of the Trastuzumab segment in the Cancer Monoclonal Antibody Testing Market.
- Bevacizumab: Bevacizumab is a monoclonal antibody inhibiting angiogenesis, used in the treatment of various cancers. Increasing applications for angiogenesis testing, research on combination therapies, and collaborations drive growth in the Bevacizumab segment of the Cancer Monoclonal Antibody Testing Market.
- Cetuximab: Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) in cancer treatment. Rising focus on EGFR testing, exploration of biomarker combinations, and technological advancements characterize the Cetuximab segment in the Cancer Monoclonal Antibody Testing Market.
- Others: The “Others” segment includes various monoclonal antibodies with diverse cancer applications. Ongoing research for novel biomarkers, collaborations for diversified applications, and a focus on rare cancers contribute to the dynamic growth of the “Others” segment in the Cancer Monoclonal Antibody Testing Market.
By Testing Method
- Immunohistochemistry (IHC): IHC is a method of detecting proteins in tissue samples. In the Cancer Monoclonal Antibody Testing Market, IHC provides precise localization of biomarkers, aiding in cancer diagnosis. Trends include increased use of predictive and prognostic markers and continuous improvement in antibody specificity.
- Flow Cytometry: Flow cytometry assesses cell properties. In the Cancer Monoclonal Antibody Testing Market, it aids in identifying cancer cells. Trends involve high-throughput capabilities, multiparametric analysis, and integration with other technologies for comprehensive cellular profiling.
- Polymerase Chain Reaction (PCR): PCR amplifies DNA segments. In the Cancer Monoclonal Antibody Testing Market, PCR detects genetic alterations. Trends include the adoption of real-time PCR for quantitative analysis and the development of PCR-based companion diagnostics.
- Next-Generation Sequencing (NGS): NGS analyzes DNA sequences. In the Cancer Monoclonal Antibody Testing Market, NGS offers comprehensive genomic profiling for personalized cancer treatment. Trends involve cost reduction, increased speed, and expanded applications in precision oncology.
- Others: Other testing methods in the Cancer Monoclonal Antibody Testing Market encompass various techniques like enzyme-linked immunosorbent assay (ELISA) and fluorescence in situ hybridization (FISH). Trends include the exploration of novel methods, combining technologies for enhanced diagnostic accuracy, and expanded applications.
By End User
- Hospitals: Hospitals are key end-users of Cancer Monoclonal Antibody Testing, employing these tests for accurate cancer diagnosis and treatment planning. Trends include the integration of testing into routine care, enhancing in-house diagnostic capabilities, and increasing collaborations with pharmaceutical companies for comprehensive patient management.
- Diagnostic Laboratories: Diagnostic laboratories utilize Cancer Monoclonal Antibody Testing for precise cancer detection. Trends involve increased automation, adoption of advanced technologies for efficient testing, and partnerships with research institutions to stay abreast of innovative testing methodologies.
- Research Institutions: Research institutions play a pivotal role in advancing Cancer Monoclonal Antibody Testing. Trends include extensive R&D efforts, collaboration with industry players for technology transfer, and a focus on developing novel biomarkers and testing methods for improved diagnostic accuracy.
- Others: Other end-users encompass various healthcare facilities, clinics, and outpatient centers. Trends involve the diversification of testing services, expanding accessibility, and exploring partnerships with technology providers to integrate Cancer Monoclonal Antibody Testing into a broader spectrum of healthcare services.
Report Scope
| Feature of the Report | Details |
| Market Size in 2024 | USD 90.5 Billion |
| Projected Market Size in 2033 | USD 175.1 Billion |
| Market Size in 2023 | USD 84.1 Billion |
| CAGR Growth Rate | 7.6% CAGR |
| Base Year | 2023 |
| Forecast Period | 2024-2033 |
| Key Segment | By Type of Cancer, Monoclonal Antibody Type, Testing Method, End-User and Region |
| Report Coverage | Revenue Estimation and Forecast, Company Profile, Competitive Landscape, Growth Factors and Recent Trends |
| Regional Scope | North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America |
| Buying Options | Request tailored purchasing options to fulfil your requirements for research. |
Cancer Monoclonal Antibody Testing Market – Regional Analysis
The Cancer Monoclonal Antibody Testing Market is segmented into various regions, including North America, Europe, Asia-Pacific, and LAMEA. Here is a brief overview of each region:
- North America: In North America, the Cancer Monoclonal Antibody Testing Market witnesses a trend towards precision medicine adoption, with an emphasis on individualized treatment plans. Collaboration between research institutions and healthcare providers for large-scale clinical trials and data analysis is a notable trend, fostering innovation and personalized cancer care.
- Europe: In Europe, there is a growing trend of integrating Cancer Monoclonal Antibody Testing into routine clinical practice. The emphasis is on standardized testing protocols and cross-border collaborations, enabling efficient data sharing for improved cancer research and diagnostic accuracy.
- Asia-Pacific: The Asia-Pacific region experiences a trend of increased awareness and accessibility to Cancer Monoclonal Antibody Testing. Emerging economies focus on expanding healthcare infrastructure, leveraging telehealth solutions, and fostering partnerships with global pharmaceutical companies to enhance the availability of advanced diagnostic technologies.
- LAMEA (Latin America, Middle East, and Africa): In LAMEA, there is a trend towards addressing healthcare disparities through increased investment in Cancer Monoclonal Antibody Testing. Collaborations with international organizations, the adoption of cost-effective testing solutions, and the development of region-specific diagnostic approaches contribute to improving cancer diagnosis and treatment outcomes.
Competitive Landscape – Cancer Monoclonal Antibody Testing Market
The Cancer Monoclonal Antibody Testing Market is highly competitive, with a large number of manufacturers and retailers operating globally. Some of the key players in the market include:
- Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Bristol Myers Squibb Company
- Johnson & Johnson
- Novartis International AG
- Amgen Inc.
- AstraZeneca plc
- Eli Lilly and Company
- AbbVie Inc.
- Genentech Inc. (a subsidiary of Roche)
- Biogen Inc.
- Pfizer Inc.
- Sanofi S.A.
- Seattle Genetics Inc.
- Takeda Pharmaceutical Company Limited
- Others
These companies operate in the market through various strategies such as product innovation, mergers and acquisitions, and partnerships.
New players entering the Cancer Monoclonal Antibody Testing Market often adopt innovative approaches and technologies to establish a presence. Start-ups and smaller companies focus on research collaborations and strategic partnerships to accelerate development.
Key players like F. Hoffmann-La Roche, Merck, and Johnson & Johnson dominate the market by their extensive R&D investments, established distribution networks, and diverse product portfolios. These industry leaders leverage their financial strength to acquire innovative technologies and engage in partnerships, ensuring a competitive edge and market dominance in the evolving landscape of cancer monoclonal antibody testing.
The Cancer Monoclonal Antibody Testing Market is segmented as follows:
By Type of Cancer
- Breast Cancer
- Lung Cancer
- Colorectal Cancer
- Prostate Cancer
- Others
By Monoclonal Antibody Type
- Rituximab
- Trastuzumab
- Bevacizumab
- Cetuximab
- Others
By Testing Method
- Immunohistochemistry (IHC)
- Flow Cytometry
- Polymerase Chain Reaction (PCR)
- Next-Generation Sequencing (NGS)
- Others
By End-User
- Hospitals
- Diagnostic Laboratories
- Research Institutions
- Others
Regional Coverage:
North America
- U.S.
- Canada
- Mexico
- Rest of North America
Europe
- Germany
- France
- U.K.
- Russia
- Italy
- Spain
- Netherlands
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Taiwan
- Rest of Asia Pacific
The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
Latin America
- Brazil
- Argentina
- Rest of Latin America
Table of Contents
- Chapter 1. Preface
- 1.1 Report Description and Scope
- 1.2 Research scope
- 1.3 Research methodology
- 1.3.1 Market Research Type
- 1.3.2 Market Research Methodology
- Chapter 2. Executive Summary
- 2.1 Global Cancer Monoclonal Antibody Testing Market, (2024 – 2033) (USD Billion)
- 2.2 Global Cancer Monoclonal Antibody Testing Market: snapshot
- Chapter 3. Global Cancer Monoclonal Antibody Testing Market – Industry Analysis
- 3.1 Cancer Monoclonal Antibody Testing Market: Market Dynamics
- 3.2 Market Drivers
- 3.2.1 Rising Incidence of Cancer
- 3.2.2 Advancements in Biotechnology
- 3.2.3 Shift towards Personalized Medicine
- 3.2.4 Government Initiatives and Funding
- 3.2.5 Technological Integration and Automation
- 3.2.6 Expansion in Emerging Markets.
- 3.3 Market Restraints
- 3.4 Market Opportunities
- 3.5 Market Challenges
- 3.6 Porter’s Five Forces Analysis
- 3.7 Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type of Cancer
- 3.7.2 Market Attractiveness Analysis By Monoclonal Antibody Type
- 3.7.3 Market Attractiveness Analysis By Testing Method
- 3.7.4 Market Attractiveness Analysis By End-User
- Chapter 4. Global Cancer Monoclonal Antibody Testing Market- Competitive Landscape
- 4.1 Company market share analysis
- 4.1.1 Global Cancer Monoclonal Antibody Testing Market: Company Market Share, 2024
- 4.2 Strategic development
- 4.2.1 Acquisitions & mergers
- 4.2.2 New Product launches
- 4.2.3 Agreements, partnerships, cullaborations, and joint ventures
- 4.2.4 Research and development and Regional expansion
- 4.3 Price trend analysis
- 4.1 Company market share analysis
- Chapter 5. Global Cancer Monoclonal Antibody Testing Market – Type of Cancer Analysis
- 5.1 Global Cancer Monoclonal Antibody Testing Market Overview: By Type of Cancer
- 5.1.1 Global Cancer Monoclonal Antibody Testing Market Share, By Type of Cancer, 2024 and – 2033
- 5.2 Breast Cancer
- 5.2.1 Global Cancer Monoclonal Antibody Testing Market by Breast Cancer, 2024 – 2033 (USD Billion)
- 5.3 Lung Cancer
- 5.3.1 Global Cancer Monoclonal Antibody Testing Market by Lung Cancer, 2024 – 2033 (USD Billion)
- 5.4 Colorectal Cancer
- 5.4.1 Global Cancer Monoclonal Antibody Testing Market by Colorectal Cancer, 2024 – 2033 (USD Billion)
- 5.5 Prostate Cancer
- 5.5.1 Global Cancer Monoclonal Antibody Testing Market by Prostate Cancer, 2024 – 2033 (USD Billion)
- 5.6 Others
- 5.6.1 Global Cancer Monoclonal Antibody Testing Market by Others, 2024 – 2033 (USD Billion)
- 5.1 Global Cancer Monoclonal Antibody Testing Market Overview: By Type of Cancer
- Chapter 6. Global Cancer Monoclonal Antibody Testing Market – Monoclonal Antibody Type Analysis
- 6.1 Global Cancer Monoclonal Antibody Testing Market Overview: By Monoclonal Antibody Type
- 6.1.1 Global Cancer Monoclonal Antibody Testing Market Share, By Monoclonal Antibody Type, 2024 and – 2033
- 6.2 Rituximab
- 6.2.1 Global Cancer Monoclonal Antibody Testing Market by Rituximab, 2024 – 2033 (USD Billion)
- 6.3 Trastuzumab
- 6.3.1 Global Cancer Monoclonal Antibody Testing Market by Trastuzumab, 2024 – 2033 (USD Billion)
- 6.4 Bevacizumab
- 6.4.1 Global Cancer Monoclonal Antibody Testing Market by Bevacizumab, 2024 – 2033 (USD Billion)
- 6.5 Cetuximab
- 6.5.1 Global Cancer Monoclonal Antibody Testing Market by Cetuximab, 2024 – 2033 (USD Billion)
- 6.6 Others
- 6.6.1 Global Cancer Monoclonal Antibody Testing Market by Others, 2024 – 2033 (USD Billion)
- 6.1 Global Cancer Monoclonal Antibody Testing Market Overview: By Monoclonal Antibody Type
- Chapter 7. Global Cancer Monoclonal Antibody Testing Market – Testing Method Analysis
- 7.1 Global Cancer Monoclonal Antibody Testing Market Overview: By Testing Method
- 7.1.1 Global Cancer Monoclonal Antibody Testing Market Share, By Testing Method, 2024 and – 2033
- 7.2 Immunohistochemistry (IHC)
- 7.2.1 Global Cancer Monoclonal Antibody Testing Market by Immunohistochemistry (IHC), 2024 – 2033 (USD Billion)
- 7.3 Flow Cytometry
- 7.3.1 Global Cancer Monoclonal Antibody Testing Market by Flow Cytometry, 2024 – 2033 (USD Billion)
- 7.4 Polymerase Chain Reaction (PCR)
- 7.4.1 Global Cancer Monoclonal Antibody Testing Market by Polymerase Chain Reaction (PCR), 2024 – 2033 (USD Billion)
- 7.5 Next-Generation Sequencing (NGS)
- 7.5.1 Global Cancer Monoclonal Antibody Testing Market by Next-Generation Sequencing (NGS), 2024 – 2033 (USD Billion)
- 7.6 Others
- 7.6.1 Global Cancer Monoclonal Antibody Testing Market by Others, 2024 – 2033 (USD Billion)
- 7.1 Global Cancer Monoclonal Antibody Testing Market Overview: By Testing Method
- Chapter 8. Global Cancer Monoclonal Antibody Testing Market – End-User Analysis
- 8.1 Global Cancer Monoclonal Antibody Testing Market Overview: By End-User
- 8.1.1 Global Cancer Monoclonal Antibody Testing Market Share, By End-User, 2024 and – 2033
- 8.2 Hospitals
- 8.2.1 Global Cancer Monoclonal Antibody Testing Market by Hospitals, 2024 – 2033 (USD Billion)
- 8.3 Diagnostic Laboratories
- 8.3.1 Global Cancer Monoclonal Antibody Testing Market by Diagnostic Laboratories, 2024 – 2033 (USD Billion)
- 8.4 Research Institutions
- 8.4.1 Global Cancer Monoclonal Antibody Testing Market by Research Institutions, 2024 – 2033 (USD Billion)
- 8.5 Others
- 8.5.1 Global Cancer Monoclonal Antibody Testing Market by Others, 2024 – 2033 (USD Billion)
- 8.1 Global Cancer Monoclonal Antibody Testing Market Overview: By End-User
- Chapter 9. Cancer Monoclonal Antibody Testings Market – Regional Analysis
- 9.1 Global Cancer Monoclonal Antibody Testings Market Regional Overview
- 9.2 Global Cancer Monoclonal Antibody Testings Market Share, by Region, 2024 & – 2033 (USD Billion)
- 9.3. North America
- 9.3.1 North America Cancer Monoclonal Antibody Testings Market, 2024 – 2033 (USD Billion)
- 9.3.1.1 North America Cancer Monoclonal Antibody Testings Market, by Country, 2024 – 2033 (USD Billion)
- 9.3.1 North America Cancer Monoclonal Antibody Testings Market, 2024 – 2033 (USD Billion)
- 9.4 North America Cancer Monoclonal Antibody Testings Market, by Type of Cancer, 2024 – 2033
- 9.4.1 North America Cancer Monoclonal Antibody Testings Market, by Type of Cancer, 2024 – 2033 (USD Billion)
- 9.5 North America Cancer Monoclonal Antibody Testings Market, by Monoclonal Antibody Type, 2024 – 2033
- 9.5.1 North America Cancer Monoclonal Antibody Testings Market, by Monoclonal Antibody Type, 2024 – 2033 (USD Billion)
- 9.6 North America Cancer Monoclonal Antibody Testings Market, by Testings Method, 2024 – 2033
- 9.6.1 North America Cancer Monoclonal Antibody Testings Market, by Testings Method, 2024 – 2033 (USD Billion)
- 9.7 North America Cancer Monoclonal Antibody Testings Market, by End-User, 2024 – 2033
- 9.7.1 North America Cancer Monoclonal Antibody Testings Market, by End-User, 2024 – 2033 (USD Billion)
- 9.8. Europe
- 9.8.1 Europe Cancer Monoclonal Antibody Testings Market, 2024 – 2033 (USD Billion)
- 9.8.1.1 Europe Cancer Monoclonal Antibody Testings Market, by Country, 2024 – 2033 (USD Billion)
- 9.8.1 Europe Cancer Monoclonal Antibody Testings Market, 2024 – 2033 (USD Billion)
- 9.9 Europe Cancer Monoclonal Antibody Testings Market, by Type of Cancer, 2024 – 2033
- 9.9.1 Europe Cancer Monoclonal Antibody Testings Market, by Type of Cancer, 2024 – 2033 (USD Billion)
- 9.10 Europe Cancer Monoclonal Antibody Testings Market, by Monoclonal Antibody Type, 2024 – 2033
- 9.10.1 Europe Cancer Monoclonal Antibody Testings Market, by Monoclonal Antibody Type, 2024 – 2033 (USD Billion)
- 9.11 Europe Cancer Monoclonal Antibody Testings Market, by Testings Method, 2024 – 2033
- 9.11.1 Europe Cancer Monoclonal Antibody Testings Market, by Testings Method, 2024 – 2033 (USD Billion)
- 9.12 Europe Cancer Monoclonal Antibody Testings Market, by End-User, 2024 – 2033
- 9.12.1 Europe Cancer Monoclonal Antibody Testings Market, by End-User, 2024 – 2033 (USD Billion)
- 9.13. Asia Pacific
- 9.13.1 Asia Pacific Cancer Monoclonal Antibody Testings Market, 2024 – 2033 (USD Billion)
- 9.13.1.1 Asia Pacific Cancer Monoclonal Antibody Testings Market, by Country, 2024 – 2033 (USD Billion)
- 9.13.1 Asia Pacific Cancer Monoclonal Antibody Testings Market, 2024 – 2033 (USD Billion)
- 9.14 Asia Pacific Cancer Monoclonal Antibody Testings Market, by Type of Cancer, 2024 – 2033
- 9.14.1 Asia Pacific Cancer Monoclonal Antibody Testings Market, by Type of Cancer, 2024 – 2033 (USD Billion)
- 9.15 Asia Pacific Cancer Monoclonal Antibody Testings Market, by Monoclonal Antibody Type, 2024 – 2033
- 9.15.1 Asia Pacific Cancer Monoclonal Antibody Testings Market, by Monoclonal Antibody Type, 2024 – 2033 (USD Billion)
- 9.16 Asia Pacific Cancer Monoclonal Antibody Testings Market, by Testings Method, 2024 – 2033
- 9.16.1 Asia Pacific Cancer Monoclonal Antibody Testings Market, by Testings Method, 2024 – 2033 (USD Billion)
- 9.17 Asia Pacific Cancer Monoclonal Antibody Testings Market, by End-User, 2024 – 2033
- 9.17.1 Asia Pacific Cancer Monoclonal Antibody Testings Market, by End-User, 2024 – 2033 (USD Billion)
- 9.18. Latin America
- 9.18.1 Latin America Cancer Monoclonal Antibody Testings Market, 2024 – 2033 (USD Billion)
- 9.18.1.1 Latin America Cancer Monoclonal Antibody Testings Market, by Country, 2024 – 2033 (USD Billion)
- 9.18.1 Latin America Cancer Monoclonal Antibody Testings Market, 2024 – 2033 (USD Billion)
- 9.19 Latin America Cancer Monoclonal Antibody Testings Market, by Type of Cancer, 2024 – 2033
- 9.19.1 Latin America Cancer Monoclonal Antibody Testings Market, by Type of Cancer, 2024 – 2033 (USD Billion)
- 9.20 Latin America Cancer Monoclonal Antibody Testings Market, by Monoclonal Antibody Type, 2024 – 2033
- 9.20.1 Latin America Cancer Monoclonal Antibody Testings Market, by Monoclonal Antibody Type, 2024 – 2033 (USD Billion)
- 9.21 Latin America Cancer Monoclonal Antibody Testings Market, by Testings Method, 2024 – 2033
- 9.21.1 Latin America Cancer Monoclonal Antibody Testings Market, by Testings Method, 2024 – 2033 (USD Billion)
- 9.22 Latin America Cancer Monoclonal Antibody Testings Market, by End-User, 2024 – 2033
- 9.22.1 Latin America Cancer Monoclonal Antibody Testings Market, by End-User, 2024 – 2033 (USD Billion)
- 9.23. The Middle-East and Africa
- 9.23.1 The Middle-East and Africa Cancer Monoclonal Antibody Testings Market, 2024 – 2033 (USD Billion)
- 9.23.1.1 The Middle-East and Africa Cancer Monoclonal Antibody Testings Market, by Country, 2024 – 2033 (USD Billion)
- 9.23.1 The Middle-East and Africa Cancer Monoclonal Antibody Testings Market, 2024 – 2033 (USD Billion)
- 9.24 The Middle-East and Africa Cancer Monoclonal Antibody Testings Market, by Type of Cancer, 2024 – 2033
- 9.24.1 The Middle-East and Africa Cancer Monoclonal Antibody Testings Market, by Type of Cancer, 2024 – 2033 (USD Billion)
- 9.25 The Middle-East and Africa Cancer Monoclonal Antibody Testings Market, by Monoclonal Antibody Type, 2024 – 2033
- 9.25.1 The Middle-East and Africa Cancer Monoclonal Antibody Testings Market, by Monoclonal Antibody Type, 2024 – 2033 (USD Billion)
- 9.26 The Middle-East and Africa Cancer Monoclonal Antibody Testings Market, by Testings Method, 2024 – 2033
- 9.26.1 The Middle-East and Africa Cancer Monoclonal Antibody Testings Market, by Testings Method, 2024 – 2033 (USD Billion)
- 9.27 The Middle-East and Africa Cancer Monoclonal Antibody Testings Market, by End-User, 2024 – 2033
- 9.27.1 The Middle-East and Africa Cancer Monoclonal Antibody Testings Market, by End-User, 2024 – 2033 (USD Billion)
- Chapter 10. Company Profiles
- 10.1 F. Hoffmann-La Roche Ltd.
- 10.1.1 Overview
- 10.1.2 Financials
- 10.1.3 Product Portfolio
- 10.1.4 Business Strategy
- 10.1.5 Recent Developments
- 10.2 Merck & Co. Inc.
- 10.2.1 Overview
- 10.2.2 Financials
- 10.2.3 Product Portfolio
- 10.2.4 Business Strategy
- 10.2.5 Recent Developments
- 10.3 Bristol Myers Squibb Company
- 10.3.1 Overview
- 10.3.2 Financials
- 10.3.3 Product Portfolio
- 10.3.4 Business Strategy
- 10.3.5 Recent Developments
- 10.4 Johnson & Johnson
- 10.4.1 Overview
- 10.4.2 Financials
- 10.4.3 Product Portfolio
- 10.4.4 Business Strategy
- 10.4.5 Recent Developments
- 10.5 Novartis International AG
- 10.5.1 Overview
- 10.5.2 Financials
- 10.5.3 Product Portfolio
- 10.5.4 Business Strategy
- 10.5.5 Recent Developments
- 10.6 Amgen Inc.
- 10.6.1 Overview
- 10.6.2 Financials
- 10.6.3 Product Portfolio
- 10.6.4 Business Strategy
- 10.6.5 Recent Developments
- 10.7 AstraZeneca plc
- 10.7.1 Overview
- 10.7.2 Financials
- 10.7.3 Product Portfolio
- 10.7.4 Business Strategy
- 10.7.5 Recent Developments
- 10.8 Eli Lilly and Company
- 10.8.1 Overview
- 10.8.2 Financials
- 10.8.3 Product Portfolio
- 10.8.4 Business Strategy
- 10.8.5 Recent Developments
- 10.9 AbbVie Inc.
- 10.9.1 Overview
- 10.9.2 Financials
- 10.9.3 Product Portfolio
- 10.9.4 Business Strategy
- 10.9.5 Recent Developments
- 10.10 Genentech Inc. (a subsidiary of Roche)
- 10.10.1 Overview
- 10.10.2 Financials
- 10.10.3 Product Portfolio
- 10.10.4 Business Strategy
- 10.10.5 Recent Developments
- 10.11 Biogen Inc.
- 10.11.1 Overview
- 10.11.2 Financials
- 10.11.3 Product Portfolio
- 10.11.4 Business Strategy
- 10.11.5 Recent Developments
- 10.12 Pfizer Inc.
- 10.12.1 Overview
- 10.12.2 Financials
- 10.12.3 Product Portfolio
- 10.12.4 Business Strategy
- 10.12.5 Recent Developments
- 10.13 Sanofi S.A.
- 10.13.1 Overview
- 10.13.2 Financials
- 10.13.3 Product Portfolio
- 10.13.4 Business Strategy
- 10.13.5 Recent Developments
- 10.14 Seattle Genetics Inc.
- 10.14.1 Overview
- 10.14.2 Financials
- 10.14.3 Product Portfolio
- 10.14.4 Business Strategy
- 10.14.5 Recent Developments
- 10.15 Takeda Pharmaceutical Company Limited
- 10.15.1 Overview
- 10.15.2 Financials
- 10.15.3 Product Portfolio
- 10.15.4 Business Strategy
- 10.15.5 Recent Developments
- 10.16 Others.
- 10.16.1 Overview
- 10.16.2 Financials
- 10.16.3 Product Portfolio
- 10.16.4 Business Strategy
- 10.16.5 Recent Developments
- 10.1 F. Hoffmann-La Roche Ltd.
List Of Figures
Figures No 1 to 37
List Of Tables
Tables No 1 to 102
Report Methodology
In order to get the most precise estimates and forecasts possible, Custom Market Insights applies a detailed and adaptive research methodology centered on reducing deviations. For segregating and assessing quantitative aspects of the market, the company uses a combination of top-down and bottom-up approaches. Furthermore, data triangulation, which examines the market from three different aspects, is a recurring theme in all of our research reports. The following are critical components of the methodology used in all of our studies:
Preliminary Data Mining
On a broad scale, raw market information is retrieved and compiled. Data is constantly screened to make sure that only substantiated and verified sources are taken into account. Furthermore, data is mined from a plethora of reports in our archive and also a number of reputed & reliable paid databases. To gain a detailed understanding of the business, it is necessary to know the entire product life cycle and to facilitate this, we gather data from different suppliers, distributors, and buyers.
Surveys, technological conferences, and trade magazines are used to identify technical issues and trends. Technical data is also gathered from the standpoint of intellectual property, with a focus on freedom of movement and white space. The dynamics of the industry in terms of drivers, restraints, and valuation trends are also gathered. As a result, the content created contains a diverse range of original data, which is then cross-validated and verified with published sources.
Statistical Model
Simulation models are used to generate our business estimates and forecasts. For each study, a one-of-a-kind model is created. Data gathered for market dynamics, the digital landscape, development services, and valuation patterns are fed into the prototype and analyzed concurrently. These factors are compared, and their effect over the projected timeline is quantified using correlation, regression, and statistical modeling. Market forecasting is accomplished through the use of a combination of economic techniques, technical analysis, industry experience, and domain knowledge.
Short-term forecasting is typically done with econometric models, while long-term forecasting is done with technological market models. These are based on a synthesis of the technological environment, legal frameworks, economic outlook, and business regulations. Bottom-up market evaluation is favored, with crucial regional markets reviewed as distinct entities and data integration to acquire worldwide estimates. This is essential for gaining a thorough knowledge of the industry and ensuring that errors are kept to a minimum.
Some of the variables taken into account for forecasting are as follows:
• Industry drivers and constraints, as well as their current and projected impact
• The raw material case, as well as supply-versus-price trends
• Current volume and projected volume growth through 2032
We allocate weights to these variables and use weighted average analysis to determine the estimated market growth rate.
Primary Validation
This is the final step in our report’s estimating and forecasting process. Extensive primary interviews are carried out, both in-person and over the phone, to validate our findings and the assumptions that led to them.
Leading companies from across the supply chain, including suppliers, technology companies, subject matter experts, and buyers, use techniques like interviewing to ensure a comprehensive and non-biased overview of the business. These interviews are conducted all over the world, with the help of local staff and translators, to overcome language barriers.
Primary interviews not only aid with data validation, but also offer additional important insight into the industry, existing business scenario, and future projections, thereby improving the quality of our reports.
All of our estimates and forecasts are validated through extensive research work with key industry participants (KIPs), which typically include:
• Market leaders
• Suppliers of raw materials
• Suppliers of raw materials
• Buyers.
The following are the primary research objectives:
• To ensure the accuracy and acceptability of our data.
• Gaining an understanding of the current market and future projections.
Data Collection Matrix
| Perspective | Primary research | Secondary research |
| Supply-side |
|
|
| Demand-side |
|
|
Market Analysis Matrix
| Qualitative analysis | Quantitative analysis |
|
|
Prominent Player
- Hoffmann-La Roche Ltd.
- Merck & Co. Inc.
- Bristol Myers Squibb Company
- Johnson & Johnson
- Novartis International AG
- Amgen Inc.
- AstraZeneca plc
- Eli Lilly and Company
- AbbVie Inc.
- Genentech Inc. (a subsidiary of Roche)
- Biogen Inc.
- Pfizer Inc.
- Sanofi S.A.
- Seattle Genetics Inc.
- Takeda Pharmaceutical Company Limited
- Others
FAQs
The key factors driving the Market are Rising Incidence of Cancer, Advancements in Biotechnology, Shift towards Personalized Medicine, Government Initiatives and Funding, Technological Integration and Automation And Expansion in Emerging Markets.
The “Immunohistochemistry (IHC)” category dominated the market in 2023.
The key players in the market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., Bristol Myers Squibb Company, Johnson & Johnson, Novartis International AG, Amgen Inc., AstraZeneca plc, Eli Lilly and Company, AbbVie Inc., Genentech Inc. (a subsidiary of Roche), Biogen Inc., Pfizer Inc., Sanofi S.A., Seattle Genetics Inc., Takeda Pharmaceutical Company Limited, Others.
“Europe” had the largest share in the Cancer Monoclonal Antibody Testing Market.
The global market is projected to grow at a CAGR of 7.6% during the forecast period, 2024-2033.
The Cancer Monoclonal Antibody Testing Market size was valued at USD 90.5 Billion in 2024.